Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus

International Journal of Artificial Organs

Volumn 34, Issue 9, 2011, Pages 799-810

  Pietrocola, Giampiero ^a   Arciola, Carla Renata ^b   Rindi, Simonetta ^a   di Poto, Antonella ^a   Missineo, Antonino ^a   Montanaro, Lucio ^b   Speziale, Pietro ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Innate immunity; Ligand; Staphylococcus; TLR

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BACTERIA; DIMERS; GENE EXPRESSION; LIGANDS; MACROPHAGES; MAMMALS; PATTERN RECOGNITION;

CELL/B.E; HETERODIMERS; IMMUNE CELLS; IMMUNE DEFENSE; INNATE IMMUNES; INNATE IMMUNITY; PATHOGEN-ASSOCIATED MOLECULAR PATTERNS; PATTERN RECOGNITION RECEPTORS; STAPHYLOCOCCUS; TOLL-LIKE RECEPTORS;

IMMUNE SYSTEM;

BACTERIAL PROTEIN; HETERODIMER; I KAPPA B ALPHA; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; LIPOPROTEIN; LIPOTEICHOIC ACID; LYMPHOCYTE ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PANTON VALENTINE LEUKOCIDIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PEPTIDES AND PROTEINS; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN RECOGNITION; B LYMPHOCYTE; CELL ACTIVATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOCYTOSIS; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; UPREGULATION;

EID: 81355142848     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000030     Document Type: Review

References (96)

1. Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. Etiology of implant orthopedic infections: a survey on 1027 clinical isolates. Int J Artif Organs. 2005;28(11):1091-1100.
2. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials. 2006;27(11):2331-2339. Medline. doi:10.1016/j.biomaterials.2005.11.044
3. Campoccia D, Montanaro L, Visai L, et al. Characterization of 26 Staphylococcus warneri isolates from orthopedic infections. Int J Artif Organs. 2010;33(9):575-581.
4. Speziale P, Pietrocola G, Rindi S, et al. Structural and functional role of Staphylococcus aureus surface components recognizing adhesive matrix molecules of the host. Future Microbiol. 2009;4(10):1337-1352. Medline. doi:10.2217/fmb.09.102
5. Foster TJ. Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. Vet Dermatol. 2009;20(5-6):456-470. Medline. doi:10.1111/j.1365-3164.2009.00825.x
6. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol. 2010;64:143-162. Medline. doi:10.1146/annurev.micro.112408.134309
7. Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem. 2002;383(7-8):1075-1086. Medline. doi:10.1515/BC.2002.116
8. Fowler T, Wann ER, Joh D, Johansson S, Foster TJ, Höök M. Cellular invasion by Staphylococcus aureus involves a fibronectin bridge between the bacterial fibronectin-binding MSCRAMMs and host cell beta1 integrins. Eur J Cell Biol. 2000;79(10):672-679. Medline. doi:10.1078/0171-9335-00104
9. Sinha B, Francois PP, Nüsse O, et al. Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol.1999;1(2):101-117. Medline. doi:10.1046/j.1462-5822.1999.00011.x
10. Palmqvist N, Foster TJ, Tarkowski A, Josefsson E. Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death. Microb Pathog. 2002;33(5):239-249. Medline. doi:10.1006/mpat.2002.0533
11. Hair PS, Ward MD, Semmens OJ, Foster TJ, Cunnion KM. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleav age of C3b. J Infect Dis. 2008;198(1):125-133. Medline. doi:10.1086/588825
12. Jongerius I, Köhl J, Pandey MK, et al. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med. 2007;204(10):2461-2471. Medline. doi:10.1084/jem.20070818
13. Smeltzer MS, Lee CY, Harik N, Hart ME. Molecular basis of pathogenicity. In: Crossley KB, Jefferson KK, Archer GL, Fowler VG (eds). Staphylococci in Human Disease, Second Edition. Oxford, UK: Wiley-Blackwell; 2009:65-108. doi: 10.1002/9781444308464.ch4
14. Fournier B, Philpott DJ. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev. 2005;18(3):521-540. Medline. doi:10.1128/ CMR.18.3.521-540.2005
15. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801. Medline. doi:10.1016/j.cell.2006.02.015
16. O'Neill LAJ, Bowie AG. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signaling. Nat Rev Immunol. 2007;7(5):353-364. Medline. doi:10.1038/ nri2079
17. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol.2007;7(3):179-190. Medline. doi:10.1038/nri2038
18. Matsushima N, Tanaka T, Enkhbayar T, et al. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genomics.2007;8:124. Medline. doi:10.1186/1471-2164-8-124
19. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol.2004;4(7):499-511. Medline. doi:10.1038/nri1391
20. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol. 2005;174(5):2942-2950.
21. Buwitt-Beckmann U, Heine H, Wiesmüller KH, Jung G, Brock R, Akira S, Ulmer AJ. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem.2006;281(14):9049-9057.
22. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol. 2002;169(1):10-14.
23. Takeuchi O, Kawai T, Mühlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol.2001;13(7):933-940. Medline. doi:10.1093/intimm/13.7.933
24. Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature. 2005;433(7025):523-527. Medline. doi:10.1038/nature03253
25. Parcina M, Wendt C, Goetz F, et al. Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol.2008;181(6):3823-3833.
26. Strunk T, Power Coombs MR, Currie AJ, et al. TLR2 mediates recognition of live Staphylococcus epidermidis and clearance of bacteremia. PLoS ONE. 2010;5(4):e10111. Medline. doi:10.1371/journal.pone.0010111
27. Nichols JR, Aldrich AL, Mariani MM, Vidlak D, Esen N, Kielian T. TLR2 deficiency leads to increased Th17 infiltrates in experimental brain abscesses. J Immunol.2009;182(11):7119-7130. Medline. doi:10.4049/jimmunol.0802656
28. Kielian T, Haney A, Mayes PM, Garg S, Esen N. Tolllike receptor 2 modulates the proinflammatory milieu in Staphylococcus aureus-induced brain abscess. Infect Immun. 2005;73(11):7428-7435. Medline. doi:10.1128/ IAI.73.11.7428-7435.2005
29. Schmaler M, Jann NJ, Götz F, Landmann R. Staphylococcal lipoproteins and their role in bacterial survival in mice. Int J Med Microbiol. 2010;300(2-3):155-160. Medline. doi:10.1016/j.ijmm.2009.08.018
30. Cockayne A, Hill PJ, Powell NB, Bishop K, Sims C, Williams P. Molecular cloning of a 32-kilodalton lipoprotein component of a novel iron-regulated Staphylococcus epidermidis ABC transporter. Infect Immun.1998;66(8):3767-3774.
31. Heikkinen O, Seppala R, Tossavainen H, et al. Solution structure of the parvulin-type PPIase domain of Staphylococcus aureus PrsA-implications for the catalytic mechanism of parvulins. BMC Struct Biol. 2009;9:17. Medline. doi:10.1186/1472-6807-9-17
32. Hiron A, Borezée-Durant E, Piard JC, Juillard V. Only one of four oligopeptide transport systems mediates nitrogen nutrition in Staphylococcus aureus. J Bacteriol.2007;189(14):5119-5129. Medline. doi:10.1128/ JB.00274-07
33. Qi HY, Sankaran K, Gan K, Wu HC. Structure-function relationship of bacterial prolipoprotein diacylglyceryl transferase: functionally significant conserved regions. J Bacteriol. 1995;177(23):6820-6824. Medline.
34. Stoll H, Dengjel J, Nerz C, Götz F. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect Immun.2005;73(4):2411-2423. Medline. doi:10.1128/ IAI.73.4.2411-2423.2005
35. Kurokawa K, Lee H, Roh KB, et al. The Triacylated ATP Binding Cluster Transporter Substrate-binding Lipoprotein of Staphylococcus aureus Functions as a Native Ligand for Toll-like Receptor 2. J Biol Chem. 2009;284(13):8406-8411. Medline. doi:10.1074/jbc.M809618200
36. Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res.2002;8(6):459-463.
37. Hashimoto M, Tawaratsumida K, Kariya H, Aoyama K, Tamura T, Suda Y. Lipoprotein is a predominant Toll-like receptor 2 ligand in Staphylococcus aureus cell wall components. Int Immunol. 2006;18(2):355-362. Medline. doi:10.1093/intimm/dxh374
38. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285(5428):732-736. Medline. doi:10.1126/science.285.5428.732
39. Hashimoto M, Tawaratsumida K, Kariya H, et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol. 2006;177(5):3162-3169.
40. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130(6):1071-1082. Medline. doi:10.1016/j.cell.2007.09.008
41. Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity. 2009;31(6):873-884. Medline. doi:10.1016/j.immuni.2009.09.018
42. Mae M, Iyori M, Yasuda M, et al. The diacylated lipopeptide FSL-1 enhances phagocytosis of bacteria by macrophages through a Toll-like receptor 2-mediated signaling pathway. FEMS Immunol Med Microbiol. 2007;49(3):398-409. Medline. doi:10.1111/j.1574-695X.2007.00218.x
43. Lien E, Sellati TJ, Yoshimura A, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem. 1999;274(47):33419-33425. Medline. doi:10.1074/jbc.274.47.33419
44. Drage MG, Pecora ND, Hise AG, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009;258(1):29-37. Medline. doi:10.1016/j. cellimm.2009.03.008
45. Schmaler M, Jann NJ, Ferracin F, and Regine Landmann. T and B Cells Are Not Required for Clearing Staphylococcus aureus in Systemic Infection Despite a Strong TLR2-MyD88-Dependent T Cell Activation. J Immunol.2011;186(1):443-452. Medline. doi:10.4049/jimmunol.1001407
46. Azuma M, Sawahata R, Akao Y, et al. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One. 2010;5(9):e12550. Medline. doi:10.1371/journal.pone.0012550
47. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acidinduced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274(25):17406-17409. Medline. doi:10.1074/jbc.274.25.17406
48. Deininger S, Traub S, Aichele D, et al. Presentation of lipoteichoic acid potentiates its inflammatory activity. Immunobiology.2008;213(6):519-529. Medline. doi:10.1016/j.imbio.2008.01.001
49. Bunk S, Sigel S, Metzdorf D, et al. Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J Immunol. 2010;185(6):3708-3717. Medline. doi:10.4049/ jimmunol.0901660
50. Travassos LH, Girardin SE, Philpott DJ, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep. 2004;5(10):1000-1006. Medline. doi:10.1038/sj.embor.7400248
51. Volz T, Nega M, Buschmann J, et al. Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J. 2010;24(10):4089-4102. Medline. doi:10.1096/ fj.09-151001
52. Stevens NT, Sadovskaya I, Jabbouri S, et al. Staphylococcus epidermidis polysaccharide intercellular adhesin induces IL-8 expression in human astrocytes via a mechanism involving TLR2. Cell Microbiol. 2009;11(3):421-432. Medline. doi:10.1111/j.1462-5822.2008.01264.x
53. Hajjar AM, O'Mahony DS, Ozinsky A, et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol. 2001;166(1):15-19.
54. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med.2007;13(12):1510-1514. Medline. doi:10.1038/nm1656
55. Durantez M, Fayolle C, Casares N, et al. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine.2010;28(44):7146-7154. Medline. doi:10.1016/j.vaccine.2010.08.070
56. Montanaro L, Baldassarri L, Corazzari T, et al. Panton- Valentine leukocidin gene detected in Staphylococcus aureus strain isolated from a knee arthroprosthesis infection. Int J Artif Organs. 2009;32(9):630-634.
57. Zivkovic A, Sharif O, Stich K, et al. TLR 2 and CD14 mediate innate immunity and lung inflammation to staphylococcal Panton-Valentine Leukocidin in vivo. J Immunol.2011;186(3):1608-1617. Medline. doi:10.4049/jimmunol.1001665
58. West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol.2006;22:409-437. Medline. doi:10.1146/annurev.cellbio.21.122303.115827
59. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science.2008;321(5889):691-696. Medline. doi:10.1126/science.1158298
60. Ip WK, Sokolovska A, Charriere GM, et al. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J Immunol. 2010;184(12):7071-7081. Medline. doi:10.4049/jimmunol.1000110
61. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008;9(6):684-691. Medline. doi:10.1038/ni.1606
62. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 2007;26(22):3214-3226. Medline. doi:10.1038/sj.onc.1210413
63. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J. 2009;420(1):1-16. Medline. doi:10.1042/BJ20090272
64. Shim JH, Xiao C, Paschal AE, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19(22):2668-2681. Medline. doi:10.1101/gad.1360605
65. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 2005;6(11):1087-1095. Medline. doi:10.1038/ni1255
66. Wanke I, Steffen H, Christ C, et al. Skin commensals amplify the innate immune response to pathogens by activation of distinct signaling pathways. J Invest Dermatol.2011;131(2):382-390. Medline. doi:10.1038/jid.2010.328
67. Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19(6):615-622. Medline. doi:10.1016/j.coi.2007.09.002
68. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/ cryopyrin inflammasome. Curr Biol. 2004;14(21):1929-1934. Medline. doi:10.1016/j.cub.2004.10.027
69. Kanneganti TD, Ozören N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature. 2006;440(7081):233-236. Medline. doi:10.1038/nature04517
70. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440(7081):228-232. Medline. doi:10.1038/ nature04515
71. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell. 2006;126(6):1135-1145. Medline. doi:10.1016/j.cell.2006.07.033
72. Craven RR, Gao X, Allen IC, et al. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One. 2009;4(10):e7446. Medline. doi:10.1371/journal. pone.0007446
73. Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem. 2007;282(4):2386-2394. Medline. doi:10.1074/jbc. M610351200
74. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006;25(21):5071-5082. Medline. doi:10.1038/sj.emboj.7601378
75. Kanneganti TD, Lamkanfi M, Kim YG, et al. Pannexin 1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26(4):433-443. Medline. doi:10.1016/j.immuni.2007.03.008
76. Guenther F, Stroh P, Wagner C, Obst U, Hänsch GM. Phagocytosis of staphylococci biofilms by polymorphonuclear neutrophils: S. aureus and S. epidermidis differ with regard to their susceptibility towards the host defense. Int J Artif Organs. 2009;32(9):565-573.
77. Arciola CR. Host defense against implant infection: the ambivalent role of phagocytosis. Int J Artif Organs. 2010;33(9):565-567 Medline.
78. Meyle E, Stroh P, Günther F, Hoppy-Tichy T, Wagner C, Hänsch GM. Destruction of bacterial biofilms by polymorphonuclear neutrophils: relative contribution of phagocytosis, DNA release, and degranulation. Int J Artif Organs.2010;33(9):608-620.
79. Meng G, Rutz M, Schiemann M, et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest. 2004;113(10):1473-1481.
80. Raby AC, Le Bouder E, Colmont C, et al. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol.2009;183(1):506-517. Medline. doi:10.4049/jimmunol.0802909
81. Palsson-McDermott EM, Doyle SL, McGettrick AF, et al. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat Immunol. 2009;10(6):579-586. Medline. doi:10.1038/ni.1727
82. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol. 2007;8(6):584-591. Medline. doi:10.1038/ni1464
83. Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science.2007;318(5856):1628-1632. Medline. doi:10.1126/science.1145918
84. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010;11(2):141-147. Medline. doi:10.1038/ni.1828
85. Kumar A, Singh CN, Glybina IV, Mahmoud TH, Yu FS. Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis. J Infect Dis. 2010;201(2):255-263. Medline. doi:10.1086/649589
86. Demento SL, Eisenbarth SC, Foellmer HG, et al. Inflammasome- activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine. 2009;27(23):3013-3021. Medline.
87. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, Engebretsen IL, Bayles KW, Horswill AR, Kielian T J Immunol. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. 2011;186(11):6585-6596.
88. Heilmann C, Schweitzer O, Gerke C, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol. 1996;20:1083-1091.
89. Arciola CR, Baldassarri L, Montanaro L. In catheter infections by Staphylococcus epidermidis the intercellular adhesion (ica) locus is a molecular marker of the virulent slime-producing strains. J Biomed Mater Res.2002;59(3):557-562.
90. Montanaro L, Poggi A, Visai L, et al. Extracellular DNA in biofilms. Int J Artif Organs 2011; 34(9): 824-831.
91. Arciola CR. New concepts and new weapons in implant infections. Int J Artif Organs 2009; 32:533-6.
92. Costerton WJ, Montanaro L, Balaban N, Arciola CR. Prospecting gene therapy of implant infections. Int J Artif Organs. 2009; 32(9): 689-95. Review.
93. Bruellhoff K, Fiedler J, Möller M, Groll J, Brenner RE. Surface coating strategies to prevent biofilm formation on implant surfaces. Int J Artif Organs. 2010; 33(9): 646-653. Review.
94. Groll J, Fiedler J, Bruellhoff K, Moeller M, Brenner RE. Novel surface coatings modulating eukaryotic cell adhesion and preventing implant infection. Int J Artif Organs.2009;32(9):655-662.
95. Arciola CR, Speziale P, Montanaro L. Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections. Int J Artif Organs. 2009;32(9):635-641.
96. Costerton JW, Montanaro L, Arciola CR. Bacterial communications in implant infections: a target for an intelligence war. Int J Artif Organs. 2007;30:757-763.